Circulating growth factors as clinical biomarkers in aortic valve stenosis

Juris Hofmanis, Pēteris Tretjakovs, Ulla Rozenberga, Vitolds Mackēvičs, Mārīte Cirse, Gita Gersone, Ardis Platkājis, Jānis Dāvis Osipovs, Šimons Svirskis, Guntis Bahs

Research output: Contribution to conferenceAbstractpeer-review


Aortic valve stenosis (AS) develops with a pronounced local inflammatory response, where a variety of growth factors are involved in the process, and may have a pro-inflammatory and anti-inflammatory effect. The aim of our study was to elucidate whether circulating growth factors: growth differentiation factor 15 (GDF-15), angiopoietin-2 (Ang-2), vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2), fibroblast growth factor 21 (FGF-21) could be proposed as clinically relevant biomarkers to improve risk stratification in AS patients AS patients were classified into three groups: 16 patients with mild AS stenosis; 19 with moderate and 11 with severe AS, and 30 subjects without AS (echocardiographically approved) were selected as a control group. GDF-15, Ang-2, VEGF-A, FGF-2 and TGF-21 were measured in plasma by ELISA method. GDF-15 levels differ significantly not only when comparing AS patients with control groups (p <0.0001), but also a statistically significant difference was achieved when comparing mild degree AS patients at mild stage with control individuals. We found strong relationship of GDF-15 levels regarding AS severity degree (p <0.0001). VEGF-A, FGF-2 and FGF-21 levels were significantly higher in AS patients than in controls, but relationships regarding AS severity degree were weaker (p <0.02). ROC analysis of the study growth factors showed that GDF-15 might serve as a specific and sensitive biomarker of AS stenosis (AUV = 0.75, p = 0.0002). FGF-21 correlated with GDF-15, Ang-2, and FGF-2, but it did not reach the level to serve as a clinically relevant biomarker of AS stenosis. AV stenosis is associated with significantly increased GDF-15, VEGF-A, FGF-2 and FGF-21 levels in plasma, but only GDF-15 shows pronounced relationship regarding AS severity degree, and GDF-15 may serve as a specific and sensitive biomarker of AS stenosis.
Original languageEnglish
Publication statusPublished - 24 Mar 2021
EventRSU Research week 2021: Knowledge for Use in Practice - Rīga, Latvia
Duration: 24 Mar 202126 Mar 2021


ConferenceRSU Research week 2021: Knowledge for Use in Practice
Abbreviated titleRW2021
Internet address

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 3.4. Other publications in conference proceedings (including local)


Dive into the research topics of 'Circulating growth factors as clinical biomarkers in aortic valve stenosis'. Together they form a unique fingerprint.

Cite this